Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 11/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | GRM8 | O00222 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888871 | 0.89 | CRHR1 (0.63) | CRHR1 | |
| SCHEMBL14491024 | 0.87 | CRHR1 (0.52) | CRHR1TSHRMAPTHSD17B10KDM4E | |
| SCHEMBL14350129 | 0.87 | TSHR (0.55) | CRHR1TSHRMAPTHSD17B10KDM4E | |
| SCHEMBL1237773 | 0.85 | CRHR1 (0.65) | CRHR1TSHRMAPTHSD17B10KDM4E | |
| SCHEMBL5447883 | 0.81 | CRHR1 (0.86) | CRHR1 | |
| SCHEMBL14491028 | 0.81 | CRHR1 (0.86) | CRHR1 | |
| SCHEMBL13310496 | 0.80 | TSHR (0.51) | CRHR1TSHRMAPTHSD17B10KDM4E | |
| SCHEMBL14502126 | 0.79 | CRHR1 (0.48) | CRHR1TSHRMAPTHSD17B10KDM4E | |
| SCHEMBL5729460 | 0.78 | CRHR1 (0.69) | CRHR1MAPTHSD17B10KDM4EMAPK1 | |
| SCHEMBL12019824 | 0.78 | KDM4E (0.78) | CRHR1MAPTHSD17B10KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129382-A1 | Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses | SB PHARMCO PUERTO RICO (PR) | 2007-06-07 | — | — | US | disclosed |
| US-20070129382-A1 | Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses | SB PHARMCO PUERTO RICO (PR) | 2007-06-07 | — | — | US | disclosed |
| EP-1218381-B1 | AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES | NEUROGEN CORP (US) | 2006-12-06 | — | — | EP | disclosed |
| US-6476038-B1 | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION | 2002-11-05 | — | — | US | disclosed |
| EP-1218381-A2 | AMINO SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001023388-A2 | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129382-A1 | Crf receptor antagonists, their preparations, their pharmaceutical composition, and their uses | CRH, CRHR1, CRHR2 | CRHR1 2/4885TSHR 183/4885MAPT 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.